Aurora A Kinase Links Metabolic and Epigenetic Control of Trained Immunity

Study Background and Research Question

Trained immunity describes an adaptive-like memory state adopted by innate immune cells, allowing them to mount more robust responses upon secondary challenge. This phenomenon, distinct from classical adaptive immunity, is induced by microbial agents such as β-glucan and Bacillus Calmette-Guérin (BCG) and is underpinned by both chromatin remodeling and metabolic rewiring (Li et al., 2025, reference). The integration of metabolic and epigenetic signals is critical for establishing this memory, yet the upstream regulators governing these processes remain insufficiently defined. Aurora kinase A (AurA), a serine/threonine kinase commonly overexpressed in tumors, is known for its mitotic functions but its role in trained immunity and immune cell metabolism had not been thoroughly investigated until now.

Key Innovation from the Reference Study

Li et al. (2025) provide a mechanistic link between AurA activity and the regulation of endogenous S-adenosylmethionine (SAM) in β-glucan-induced trained immunity. Their study demonstrates that AurA inhibition disrupts the epigenetic landscape necessary for trained innate immune responses by depleting SAM, a central methyl donor required for histone methylation and transcriptional activation of inflammatory genes. Specifically, the authors map how AurA controls SAM availability through the mTOR–FOXO3–GNMT axis, directly connecting kinase signaling, metabolism, and chromatin state in immune cells [source_type: paper][source_link: https://doi.org/10.7554/eLife.104138].

Methods and Experimental Design Insights

The authors employ a comprehensive suite of experimental approaches:

• In vitro training of mouse macrophages with β-glucan, followed by pharmacological or genetic inhibition of AurA.
• ATAC-seq and RNA-seq to profile chromatin accessibility and gene expression changes upon AurA inhibition.
• Metabolomic analyses to quantify intracellular SAM levels and related metabolites.
• ChIP-qPCR for histone marks (H3K4me3, H3K36me3) at promoters of key cytokine genes (Il6, Tnf).
• In vivo tumor models to assess the effect of AurA inhibition on β-glucan-mediated tumor growth inhibition.

This integrative design enables the dissection of both molecular mechanisms and functional outcomes in the context of trained immunity.

Protocol Parameters

• assay | β-glucan training of mouse macrophages | 5 μg/mL, 24 h | establishes trained immunity phenotype | as per reference protocol | paper | source
• assay | AurA inhibition (MLN8237 or equivalent) | 100 nM, 24 h | blocks AurA activity to study impact on trained immunity | dose aligns with prior apoptosis/proliferation studies in immune and tumor cells | workflow_recommendation | product_spec
• assay | ATAC-seq | standard workflow | measures chromatin accessibility | validates epigenetic changes upon AurA inhibition | paper | source
• assay | Metabolomics (SAM quantification) | LC-MS/MS | quantifies SAM, SAH | connects metabolic state to chromatin remodeling | paper | source

Core Findings and Why They Matter

• AurA is required for β-glucan-induced trained immunity: Inhibition of AurA, either pharmacologically or genetically, significantly reduces the trained phenotype in macrophages, as evidenced by diminished cytokine production upon restimulation [source_type: paper][source_link: https://doi.org/10.7554/eLife.104138].
• Epigenetic restriction via AurA inhibition: ATAC-seq and RNA-seq reveal that blocking AurA limits chromatin accessibility and downregulates genes in JAK-STAT, TNF, and NF-κB signaling pathways.
• SAM depletion and histone methylation loss: AurA inhibition lowers intracellular SAM levels, increases nuclear FOXO3 and GNMT expression, and leads to reduced H3K4me3 and H3K36me3 at Il6 and Tnf loci, impairing inflammatory gene induction.
• Tumor growth inhibition requires intact AurA signaling: In mouse models, β-glucan's anti-tumor effects are abolished by AurA inhibition, highlighting the role of trained immunity in tumor control and suggesting that AurA is a potential target in regulating anti-tumor immune responses.

These findings provide unprecedented insight into how a mitotic kinase can integrate immune cell metabolism and epigenetic regulation, with direct implications for understanding oncogenesis and tumor progression.

Comparison with Existing Internal Articles

Recent internal resources such as Molecular Beacon and Purmorphamine have highlighted the application of MLN8237 (Alisertib) as a highly selective Aurora A kinase inhibitor for cancer biology workflows, focusing on apoptosis induction in tumor cells and tumor growth inhibition in animal models [source_type: workflow_recommendation][source_link: https://molecularbeacon.com/index.php?g=Wap&m=Article&a=detail&id=15915]. While these guides emphasize the utility of MLN8237 in dissecting oncogenic mechanisms and cell cycle regulation, Li et al. (2025) extend the understanding of Aurora A's function beyond proliferation, implicating it in immune cell memory and metabolic/epigenetic crosstalk. This expands the potential application of Aurora A inhibitors in both cancer biology and immunology research.

Limitations and Transferability

Although the study by Li et al. compellingly demonstrates AurA's role in β-glucan-induced trained immunity, there are notable limitations:

• The primary models are mouse macrophages, and while relevant, human translational studies are needed to confirm the mechanistic pathway in clinical settings.
• The work centers on β-glucan as a trained immunity inducer; it remains to be determined if similar mechanisms apply for other stimuli such as BCG or endogenous danger signals.
• Pharmacological inhibition (using agents like MLN8237) may have off-target or context-dependent effects not fully captured in this system.

Transferability to cancer immunotherapy settings is promising but requires additional validation, particularly considering the interplay between innate immune memory, tumor progression, and therapeutic intervention.

Research Support Resources

Researchers aiming to study Aurora A kinase function in cancer biology, apoptosis induction, or immune-metabolic crosstalk can utilize MLN8237 (Alisertib) (SKU A4110), a well-characterized ATP-competitive Aurora A inhibitor with broad preclinical validation [source_type: product_spec][source_link: https://www.apexbt.com/mln8237-alisertib.html]. For protocol optimization, internal resources such as the guides at Molecular Beacon and Apex Apoptosis provide practical troubleshooting strategies for robust and reproducible results in both in vitro and in vivo systems. When designing experiments to probe trained immunity or chromatin-metabolic regulation, reference the parameters and workflow suggestions above to maximize translational relevance.